Ralph Henry

Ralph Henry has a diverse work experience in the biopharmaceutical and medical technology industries. Ralph is currently serving as the Chief Technology Officer at Kuria Therapeutics since March 2022. Prior to this, Ralph held the position of EVP Biopharmaceutics and Corporate Development at INTERVEXION THERAPEUTICS, LLC, starting in 2004. In 2017, they joined VIC Technology Venture Development as the VP Life Science and Medical Technology. Ralph's career began in 1996 at the University of Arkansas, where they worked as a Distinguished Professor in Biological Sciences. During their time at the university, Ralph also co-founded InterveXion Therapeutics, a pharmaceutical R&D company focused on developing antibody-based medicines for the treatment of methamphetamine use disorder.

Ralph Henry pursued their education chronologically, starting with their Bachelor of Science in Engineering (BSE) degree at The University of Kansas from 1979 to 1984. Ralph then moved on to Kansas State University, where they obtained their Ph.D. in Membrane Protein Assembly from 1985 to 1991. Following this, Ralph pursued a postdoctoral degree at the University of Florida from 1992 to 1996, focusing on Protein targeting and transport.